Q3 Revenue Jumps 53% to $26.1M, Guidance Raised, Going Concern Warning Lifted
RCEL has more than doubled off its 52-week low of $3.22.
Summary
AVITA posted Q3 revenue of $26.1M, up 53% year over year and 20% sequentially, with gross margin at 84.0% (up 270 bps). The company raised full-year 2026 revenue guidance to $92M-$94M from $86M-$89M and reaffirmed cash flow breakeven in Q4. Most importantly, management removed the going concern qualification that had hung over the story since the Q2 report, after hitting the $85M trailing-twelve-month revenue milestone and drawing the final $10M Perceptive tranche (total borrowings now $60M). Net cash use shrank to $0.6M from $3.2M in Q2, though cash and securities stood at just $10.5M at quarter-end. Separately, CMS finalized national physician payment values and simplified billing codes for RECELL effective January 1, 2027 — a reimbursement tailwind heading into next year. The stock is trading near its 52-week high of $16.90, so the bar was high; the guidance raise plus going-concern removal is the combination that matters.
At the time of this announcement, RCEL was trading at $16.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $484.9M. The 52-week trading range was $3.22 to $16.90. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.